Fibroblasts drive differential response in immunotherapy via IL-6 in bioengineered 3D cancer constructs
Abstract
Despite various therapeutic advancements in cancer, heterogeneity in the tumor microenvironment is a major hindrance to the overall efficacy of treatment. In this study, we focus on the most abundantly found cellular stromal components - fibroblasts - which can be tumor-promoting or tumor-suppressing based on the extent of disease progression and numerous additional factors. In the studies described herein, we evaluated their role in influencing chemotherapy as well as in immunotherapy using colorectal cancer (CRC) cell line-derived 3D tumor constructs. Our initial efforts centered on common chemotherapeutic agents utilized in CRC. However, while the presence of fibroblasts often did influence chemotherapy efficacy, a clear and consistent increase or decrease in efficacy was not obvious. We then focused subsequent studies on natural killer (NK) cell-based immunotherapy efficacy. There are numerous components and pathways involved in tumorigenesis and tumor-immune cell interactions, and the crosstalk between fibroblasts and immune cells like NK cells is still not well-defined. Fibroblasts have been documented to be a major player with respect to immune modulation and understanding this in greater detail can elucidate more options for anti-tumor immunity. Specifically, we used an extracellular matrix-based hydrogel platform to generate 3D CRC constructs to evaluate how fibroblasts affect tumor cell viability in presence and absence of NK cells. In general, fibroblasts aid the tumor cells in our models. We then identify a cytokine-based pathway (interleukin 6 [IL-6]) via which activated fibroblasts engage with the tumor cells and show how NK cell effector function can be restored when the IL-6 pathway is blocked in a melanoma-based tumor-on-a-chip platform. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=118 SRC="FIGDIR/small/660473v1_ufig1.gif" ALT="Figure 1"> View larger version (24K): org.highwire.dtl.DTLVardef@53797forg.highwire.dtl.DTLVardef@4dbc83org.highwire.dtl.DTLVardef@19346deorg.highwire.dtl.DTLVardef@11d834_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- THE IMMUNE RESPONSE AGAINST CANCER IS MODULATED BY STROMAL CELL FIBRONECTIN
Alexander Lubosch, Lauren A. Pitt, … Inaam A. Nakchbandi·NeoplasiaPeer-reviewed·Jul 1, 2025
- Cancer-associated fibroblasts serve as decoys to suppress NK cell anti-cancer cytotoxicity
A. Ben-Shmuel, Y. Gruper, … R. Scherz-Shouval·bioRxiv·Nov 23, 2023
- How cancer-associated fibroblasts promote T-cell exclusion in human lung tumors: a physical perspective
J. Ackermann, C. Bernard, … M. Ben Amar·bioRxiv·Jan 16, 2024
- Fibroblast-derived Collagen VI shapes the structure and function of the tumor-immune microenvironment in clear cell renal cell carcinoma
Maximilian Wess, Grigor Andreev, … Christoph Schell·bioRxiv·Mar 23, 2026
- Targeting fibroblast activation suppresses chemotherapy-induced pro-invasive remodeling of the extracellular matrix
Anna Yui, Liyi Peng, … Madeleine Julie Oudin·bioRxiv·Sep 8, 2026
- NK cells promote cancer immunoediting through tumor-intrinsic loss of interferon-stimulated gene expression
Y. Y. Wong, L. Riggan, … T. E. O'Sullivan·bioRxiv·Nov 23, 2020